Compare Nokia Corp (NOK) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs GeneDx Holdings Corp — how do they compare? Nokia Corp trades at $10.36 (market cap $56.99B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Nokia Corp is far larger — about 28.2× GeneDx Holdings Corp's market cap, and Nokia Corp pays a 1.61% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nokia Corp for 66 Days and GeneDx Holdings Corp for 19 Days on average.
| NOK | WGS | |
|---|---|---|
Market Cap | $56.99B | $2.02B |
Volume | 69,968,204 | 734,640 |
Sector | Technology | Health |
52-Week High | $16.83 | $167.51 |
52-Week Low | $5.18 | $34.51 |
Typical Hold Time | 66 Days | 19 Days |
Enterprise Value | $55.01B | $2.05B |
Dividend Yield | 1.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.36, down 2.45% on the day, with a bearish technical signal and neutral oscillators. The company reported mixed quarterly earnings, with a beat in Q2 2026 but a miss in Q1 2026. Revenue for 2025 was $19.89 billion, with a net income margin of 3.47%. Recent news highlights partnerships in AI and satellite communications, including an expanded collaboration with Microsoft and a defense-focused satellite venture with ICEYE.
The stock presents a valuation disconnect, with a high P/E of 75.09 but strong analyst optimism—61.5% recommend Buy, with a consensus price target of $17.50. Upside catalysts include AI infrastructure demand and strategic partnerships, while risks involve competitive pressures and volatile cash flows, evidenced by a net cash outflow of $1.16 billion in 2025.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
